Close Menu

Breaking News

The proteomics firm is expected to receive $350 million in proceeds through the deal, including a $200 million private investment in public equity (PIPE) transaction.

Under the agreement, Beckman Coulter will sell and distribute Genedrive's high-throughput SARS-CoV-2 test in the US and Europe.

The assay kit also received interim authorization from Health Canada on Jan. 21 and will be used by a large Canadian provincial authority.

While the tests from Clinomics, UPenn, and Inno Diagnostics detect the SARS-CoV-2 virus, Princeton BioMeditech's test differentiates between SARS-CoV-2 and influenza.

The deal includes SeqWell's PlexWell Single-Cell Rapid Kit for plate-based single-cell RNA sequencing, which is set to launch later this month.

Four genomics startups will join Illumina's Bay Area program, while five will join the Cambridge, UK program.

The researchers said this unexpected homogeneity in the cellular identity of neuroblastoma could lead to the development of targeted treatments.

The study, which included more than 6,000 individuals and 59 facial measurements, uncovered a number of novel genetic loci associated with facial traits.

By sequencing DNA from 14 feces-containing sediment samples from Spain, investigators found commensal microbes that appear to have lived in Neanderthal guts.

News items for the week of Feb. 1, 2021.

Net proceeds from the offering will primarily support commercialization and further development of the company's DetermaRx and DetermaIO assays.

The firm's life science revenues increased nearly fivefold, while diagnostics revenues declined 13 percent year over year.

The firm will use the net proceeds for its planned $600 million acquisition of Decipher Biosciences, working capital, and other general corporate purposes.

In an SEC filing, the firm said it intends to use the IPO proceeds to support manufacturing and establish a sales and marketing team, among other activities.

The firm reported $28.2 million in revenues for the three months ended Dec. 31, 2020, beating consensus Wall Street estimates on the top and bottom lines.

The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.

The British companies will collaborate on a database to support ulcerative colitis research and identify new drug targets for the disease.

Companion bills to be introduced in the House and Senate on Thursday would task the CDC with identifying and tracking emerging SARS-CoV-2 variants.

Upon completion of the merger, which will value 23andMe at $3.5 billion, Virgin Group Acquisition Corp. will change its New York Stock Exchange ticker symbol to ME.

The Belgian Society of Medical Oncology has partnered with Illumina, OncoDNA, and PierianDx for this study, which will enroll 864 patients with advanced metastatic cancer.

For the fourth quarter, diagnostics sales increased 20 percent to CHF 4.13 billion from CHF 3.44 billion in the same quarter in 2019.

The firm attributed the revenue growth in part to $867 million in sales of molecular and antigen diagnostics for COVID-19.

The company said it has priced a public offering of 3,571,428 shares of its common stock at $70.00 per share.


Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.